<DOC>
	<DOCNO>NCT01605708</DOCNO>
	<brief_summary>The purpose study assess clinical activity refractory moderate-to-severe pruritus single intravenous ( IV ) dose REGN846 adult patient moderate-to-severe atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Study Assess Clinical Activity Sequential Dose REGN846 Refractory Pruritus Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<criteria>Inclusion criterion include , limited following : 1 . Men woman age 18 65 ; woman must postmenopausal surgically sterile 2 . Patients must apply stable dose additivefree , basic , bland emollient twice daily least 7 day baseline visit 3 . Chronic Atopic Dermatitis ( AD ) 4 . Body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive . 5 . Refractory pruritus â‰¥ 6 week screen . Pruritus associate AD condition ( ) . 6 . Itching associated AD Exclusion criterion include , limited following : 1 . A history listeriosis . 2 . Presence 1 follow tuberculosis ( TB ) criterion : 1 . A history active TB 2 . A positive QuantiFERON TB test screen visit 3 . Chest radiograph ( posterioranterior lateral view ) screen within 3 month screen visit ( radiology report must available ) result consistent prior TB infection ( include limited apical scarring , apical fibrosis , multiple calcify granuloma ) . This include noncaseating granuloma . 3 . Persistent chronic active recur infection require treatment antibiotic , antiviral , antifungal within 4 week prior screen visit . 4 . Any clinically significant physical abnormality observe screen visit . 5 . Diabetic , hypertensive , know atherosclerotic vascular disease . 6 . Hospitalization reason within 60 day screen visit . 7 . History positive human immunodeficiency virus ( HIV ) screen result screen visit . 8 . History positive blood test hepatitis B/hepatitis C positive hepatitis screen result screen visit . 9 . Known sensitivity doxycycline tetracycline . 10 . Known sensitivity component excipients investigational product formulation history hypersensitivity biologic agent . 11 . Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives ( whichever longer ) , investigational drug prior screen visit . 12 . Any medical psychiatric condition opinion investigator Regeneron , would place patient risk , interfere participation study interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Itching</keyword>
</DOC>